Emergent BioSolutions has won a $628 million deal with the US government to scale production of targeted COVID-19 vaccine candidates to make "tens to hundreds of millions" of doses available through 2021, the CDMO said Monday. As part of the agreement, the government will shell out $542.7 million to reserve bulk manufacturing capacity at Emergent's Baltimore Bayview facility, which was constructed as part of a BARDA pandemic preparedness contract signed in 2012. The remaining $85.5 million will be spent expanding fill/finish capacity at two Emergent plants at Camden in Baltimore and Rockville, Maryland. Source: Fierce Pharma 1/6/2020